Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 May 2

PMID 35494034

Authors

Fei Lin

Li-Ping Zhang

Shuang-Yan Xie

Han-Ying Huang

Xiao-Yu Chen

Tong-Chao Jiang

Ling Guo

Huan-Xin Lin

Affiliations

Soon will be listed here.

Abstract

Background: To build a predictive scoring model based on simple immune and inflammatory parameters to predict postoperative survival in patients with breast cancer.

Methods: We used a brand-new immuno-inflammatory index-pan-immune-inflammation value (PIV)-to retrospectively evaluate the relationship between PIV and overall survival (OS), and based on the results of Cox regression analysis, we established a simple scoring prediction model based on several independent prognostic parameters. The predictive accuracy of the model was evaluated and independently validated.

Results: A total of 1,312 patients were included for analysis. PIV was calculated as follows: neutrophil count (10/L) × platelet count (10/L) × monocyte count (10/L)/lymphocyte count (10/L). According to the best cutoff value of PIV, we divided the patients into two different subgroups, high PIV (PIV > 310.2) and low PIV (PIV ≤ 310.2), associated with significantly different survival outcomes (3-year OS, 80.26% vs. 86.29%, respectively; 5-year OS, 62.5% vs. 71.55%, respectively). Six independent prognostic factors were identified and used to build the scoring system, which performed well with a concordance index (C-index) of 0.759 (95% CI: 0.715-0.802); the calibration plot showed good calibration.

Conclusions: We have established and verified a simple scoring system for predicting prognosis, which can predict the survival of patients with operable breast cancer. This system can help clinicians implement targeted and individualized treatment strategies.

Citing Articles

Pan‑immune‑inflammatory values predict survival in patients after radical surgery for non‑metastatic colorectal cancer: A retrospective study.

Li K, Zeng X, Zhang Z, Wang K, Pan Y, Wu Z Oncol Lett. 2025; 29(4):197.

PMID: 40046636 PMC: 11880885. DOI: 10.3892/ol.2025.14943.

Prognostic Importance of Panimmune-Inflammation Value and PILE Scores in Non-Metastatic Luminal A Breast Cancer.

Yilmaz M, Erdis E, Ucar M, Yucel B Breast Care (Basel). 2025; 20(1):27-39.

PMID: 40046313 PMC: 11877222. DOI: 10.1159/000543304.

Predictive value of preoperative pan-immune-inflammation value index in the prognosis of oral cancer patients undergoing radical resection.

Huang W, Lin Y, Xu E, Ji Y, Wang J, Liu F BMC Oral Health. 2025; 25(1):132.

PMID: 39856710 PMC: 11761202. DOI: 10.1186/s12903-025-05477-6.

Predictive strength of inflammatory scores for in-hospital mortality in infective endocarditis.

Cicek V, Erdem A, Kilic S, Tay B, Kamil Yemis M, Taslicukur S Herz. 2025; .

PMID: 39853409 DOI: 10.1007/s00059-024-05292-9.

Comprehensive Evaluation of Inflammatory Biomarkers in Cervical Cancer Treated with Chemoradiotherapy.

Koca T, Gocen Vardar N, Aksoy R, Korcum A Curr Oncol. 2025; 32(1).

PMID: 39851955 PMC: 11763994. DOI: 10.3390/curroncol32010039.

References

Peng R, Liang Z, Chen K, Li L, Qu S, Zhu X . Nomogram Based on Lactate Dehydrogenase-to-Albumin Ratio (LAR) and Platelet-to-Lymphocyte Ratio (PLR) for Predicting Survival in Nasopharyngeal Carcinoma. J Inflamm Res. 2021; 14:4019-4033. PMC: 8385134. DOI: 10.2147/JIR.S322475. View

Cho U, Park H, Im S, Yoo C, Jung J, Suh Y . Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018; 13(7):e0200936. PMC: 6062056. DOI: 10.1371/journal.pone.0200936. View

Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H . Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer. 2013; 109(9):2316-22. PMC: 3817333. DOI: 10.1038/bjc.2013.595. View

Moldoveanu D, Pravongviengkham V, Best G, Martinez C, Hijal T, Meguerditchian A . Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer. Ann Surg Oncol. 2020; 27(10):4028-4034. DOI: 10.1245/s10434-020-08302-2. View

Zhu M, Chen L, Kong X, Wang X, Li X, Fang Y . The Systemic Immune-Inflammation Index is an Independent Predictor of Survival in Breast Cancer Patients. Cancer Manag Res. 2022; 14:775-820. PMC: 8887616. DOI: 10.2147/CMAR.S346406. View

Ma X, Jia C, Fu D, Chu M, Ding X, Wu X . Analysis of Hematological Traits in Polled Yak by Genome-Wide Association Studies Using Individual SNPs and Haplotypes. Genes (Basel). 2019; 10(6). PMC: 6627507. DOI: 10.3390/genes10060463. View

Fuca G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S . The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020; 123(3):403-409. PMC: 7403416. DOI: 10.1038/s41416-020-0894-7. View

Sato S, Shimizu T, Ishizuka M, Suda K, Shibuya N, Hachiya H . The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery. Surg Today. 2022; 52(8):1160-1169. DOI: 10.1007/s00595-021-02448-6. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

10.

Trapani D, Ginsburg O, Fadelu T, Lin N, Hassett M, Ilbawi A . Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022; 104:102339. DOI: 10.1016/j.ctrv.2022.102339. View

11.

Chen X, Hong X, Chen G, Xue J, Huang J, Wang F . The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. Transl Oncol. 2022; 17:101338. PMC: 8749135. DOI: 10.1016/j.tranon.2021.101338. View

12.

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso M . Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014; 2014:149185. PMC: 4036716. DOI: 10.1155/2014/149185. View

13.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

14.

Gregory A, Houghton A . Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011; 71(7):2411-6. DOI: 10.1158/0008-5472.CAN-10-2583. View

15.

Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W . Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. Cancer Med. 2019; 8(9):4135-4148. PMC: 6675722. DOI: 10.1002/cam4.2281. View

16.

Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C . The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021; 150:155-167. DOI: 10.1016/j.ejca.2021.03.043. View

17.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

18.

Yu P, Huang Y, Han Y, Lin L, Sun W, Rabson A . TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2 neutrophils. Oncogene. 2016; 36(4):482-490. PMC: 5290040. DOI: 10.1038/onc.2016.217. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View